TWST Stock Risk & Deep Value Analysis
Twist Bioscience Corp
Healthcare • Diagnostics & Research
DVR Score
out of 10
What You Need to Know About TWST Stock
We analyzed Twist Bioscience Corp using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran TWST through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
TWST Risk Analysis & Red Flags
What Could Go Wrong
Twist Bioscience's biggest risk is failing to achieve consistent positive free cash flow and adjusted EBITDA breakeven as guided for FY2026. If operating expenses continue to outpace accelerating revenue growth, or if market demand for synthetic DNA unexpectedly decelerates, the company could face increased capital needs and further share dilution, severely impacting investor confidence and valuation.
Risk Matrix
Overall
Aggressive
Financial
Medium
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
Low
Red Flags
- ⚠
Continued net losses, despite improving gross margin
- ⚠
Reliance on future positive free cash flow to alleviate cash burn
- ⚠
Routine but consistent insider sales (though mainly tax-related, still cash outflows)
Upcoming Risk Events
- 📅
Disappointing Q2 earnings results or lowered full-year guidance
- 📅
Delays in achieving positive free cash flow or EBITDA breakeven targets
- 📅
Increased competitive pressure or emergence of disruptive alternative technologies
When to Reconsider
- 🚪
Gross margin declines below 50% for two consecutive quarters
- 🚪
Significant deceleration in year-over-year revenue growth below 10%
- 🚪
Failure to achieve positive free cash flow by mid-2026 as guided by management
Unlock TWST Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Twist Bioscience Corp (TWST) Do?
Market Cap
$2.94B
Sector
Healthcare
Industry
Diagnostics & Research
Employees
979
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Visit Twist Bioscience Corp WebsiteInvestment Thesis
Twist Bioscience is a high-growth synthetic biology leader with a proprietary, scalable silicon-based DNA synthesis platform, strategically positioned for 10x potential across drug discovery, genomics, and the emerging DNA data storage market. With strong Q1 FY2026 results, improved gross margins, and a clear path to profitability and positive free cash flow by late 2026, the company is demonstrating strong execution on its vision for future market leadership.
Is TWST Stock Undervalued?
Unlock the full AI analysis for TWST
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
TWST Price Targets & Strategy
12-Month Target
$65.00
Bull Case
$90.00
Bear Case
$40.00
Valuation Basis
Based on 9x forward P/S ratio applied to projected FY2026 revenue of $437.5 million.
Entry Strategy
Consider dollar-cost averaging between $45-$50. Buy on dips towards the $40 support zone if market conditions allow.
Exit Strategy
Consider taking initial profits at $80-$90; implement a trailing stop-loss below the $40 level.
Portfolio Allocation
7-10% for aggressive risk tolerance; 3-5% for moderate risk tolerance.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is TWST Financially Healthy?
Valuation
EV/EBITDA
-25.70
Price/Book
4.09
Price/Sales
5.07
Profitability
Gross Margin
51.62%
Operating Margin
-34.35%
Net Margin
-19.56%
Return on Equity
-16.58%
Revenue Growth
18.59%
EPS
$-1.27
Balance Sheet
Current Ratio
3.64
Quick Ratio
3.17
Debt/Equity
0.19
Total Debt
$90.57M
Cash & Equivalents
$232.43M
Cash Flow
Operating Cash Flow
-$47.60M
Other
Beta (Volatility)
2.17
Does TWST Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
The proprietary silicon-based platform provides a significant technological and cost advantage in DNA synthesis, protected by a growing patent portfolio. This unique approach creates a barrier to entry, making it difficult for competitors to quickly replicate their scale and efficiency, thus offering a durable competitive advantage for 10-20 years.
Moat Erosion Risks
- •Emergence of a new, even more disruptive DNA synthesis technology from competitors or academic research.
- •Expiration of key patents that protect Twist's silicon-based platform.
- •Aggressive pricing strategies by larger, more established competitors.
TWST Competitive Moat Analysis
Sign up to see competitive advantages
TWST Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral to Bullish. The innovative nature of their technology and high growth potential often generate retail interest, but current unprofitability fosters caution.
Institutional Sentiment
Positive. Evercore ISI raised price target to $56 and maintained an 'Outperform' rating. Overall institutional interest is likely strong given the company's position in a high-growth sector.
Insider Activity (Form 4)
Officer Dennis Cho sold 354 shares at $43.7864/share (tax sell-to-cover on RSU vesting). SVP Human Resources Paula Green sold 297 shares at $43.7864/share (tax sell-to-cover on RSU vesting). Director Robert B. Chess sold 2,184 shares on 02/13/2026 for $105,401.37 (option exercise). Form 144 notices for unnamed affiliate and Fidelity indicate proposed sales, typically for RSU vesting or portfolio rebalancing. No significant bearish insider selling by key executives.
Options Flow
Normal options activity; no specific unusual options flow data available.
Earnings Intelligence
Next Earnings
2026-05-04
Surprise Probability
Medium
Historical Earnings Pattern
Given recent Q1 fiscal 2026 beat and raised guidance, the stock is likely to react positively to continued strong performance or improved outlook, and negatively to any misses or lowered guidance, particularly regarding profitability milestones.
Key Metrics to Watch
Competitive Position
Top Competitor
GH (Ginkgo Bioworks)
Market Share Trend
Gaining. New product launches and strategic agreements, coupled with sustained revenue growth, indicate an expanding market presence.
Valuation vs Peers
Likely trading at a premium Price-to-Sales (P/S) ratio compared to some established biotech companies, but potentially in line with other high-growth, innovative platform biotechs that are pre-profitability.
Competitive Advantages
- •Proprietary silicon-based DNA synthesis platform offering high throughput, accuracy, and cost efficiency.
- •Broad product portfolio catering to diverse applications in genomics, drug discovery, and emerging fields.
- •Significant intellectual property (IP) protecting their core technology.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive TWST Stock Higher?
Near-Term (0-6 months)
- •Q2 Fiscal 2026 Earnings on 2026-05-04
- •Increased adoption of newly launched next-generation library preparation kits
- •Progress updates on expanded antibody discovery via bispecific licensing agreement
Medium-Term (6-18 months)
- •Achievement of positive free cash flow (guided for early 2026)
- •Achievement of adjusted EBITDA breakeven (guided for late FY2026)
- •New strategic partnerships or major customer agreements
- •Further expansion into new synthetic biology applications (e.g., in vivo gene editing tools)
Long-Term (18+ months)
- •Realization of significant revenue streams from DNA data storage applications
- •Consolidation of market leadership in advanced synthetic biology tools
- •Potential M&A activity within the fragmented synthetic biology industry
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for TWST?
- ✓
Acceleration in customer adoption rates and order volumes for new products.
- ✓
Consistent gross margin expansion and evidence of operating leverage.
- ✓
Confirmed achievement of positive free cash flow and EBITDA breakeven milestones.
Bull Case Analysis
See what could go right with Premium
Competing with TWST
See how Twist Bioscience Corp compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Twist Bioscience Corp TWST | $2.9B | 7.5 | — | $376.6M | -19.6% | 18.6% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Twist Bioscience Corp Makes Money
Twist Bioscience manufactures and sells custom synthetic DNA products and services, acting as a foundational technology provider for the rapidly expanding synthetic biology, genomics, and biopharma industries. They utilize a proprietary silicon-based DNA synthesis platform to produce high-quality, custom DNA sequences, genes, and oligo pools at unprecedented scale and cost-efficiency. This enables researchers, pharmaceutical companies, and other industries to accelerate R&D in areas like drug discovery, diagnostics, sustainable chemicals, and even next-generation data storage, providing the fundamental building blocks of biology.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Twist Bioscience Corp (TWST)?
As of April 13, 2026, Twist Bioscience Corp has a DVR Score of 7.5 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Twist Bioscience Corp?
Twist Bioscience Corp's market capitalization is approximately $2.9B. The company operates in the Healthcare sector within the Diagnostics & Research industry.
What ticker symbol does Twist Bioscience Corp use?
TWST is the ticker symbol for Twist Bioscience Corp. The company trades on the NMS.
What is the risk level for TWST stock?
Our analysis rates Twist Bioscience Corp's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
Is Twist Bioscience Corp's revenue growing?
Twist Bioscience Corp has reported revenue growth of 18.6%. The company is showing strong top-line momentum.
Is TWST stock profitable?
Twist Bioscience Corp has a profit margin of -19.6%. The company is currently unprofitable.
How often is the TWST DVR analysis updated?
Our AI-powered analysis of Twist Bioscience Corp is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 13, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for TWST (Twist Bioscience Corp) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.